Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-27
2007-11-27
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S332000
Reexamination Certificate
active
10911988
ABSTRACT:
Integrin receptor antagonists whose molecular structure includes a tetrahydropyridimidinylaminoethyloxybenzoyl group on a sulfonylamino-β-alanine nucleus exhibit increased binding affinity for the αvβ3 receptor when further substituted on the sulfonyl moiety with an N-amino alkycarbamyl group or a butyloxycarbonylamino alkylcarbamoyl group or similar groups.
REFERENCES:
patent: 5741796 (1998-04-01), Hartman et al.
patent: 2002/0071843 (2002-06-01), Li et al.
patent: 2003/0186987 (2003-10-01), Kees et al.
patent: WO 99/52879 (1999-10-01), None
Agrez et al., The alpha-v-beta-6 Integrin induces gelatinase B secretion in colon cancer cells, Int. J. Cancer, 81, pp. 90-97, 1999.
Brooks et al., Integrin alpha-v-beta-3: A therapeutic target, DN&P, 10(8), pp. 456-461, Oct. 1997.
Gladson et al., Vitronectin Expression in Differentiating Neuroblastic Tumors, American Journal of Pathology, vol. 150, No. 5, pp. 1631-1646, May 1997.
Kim et al., Vitronectin-driven Human Keratinocyte Locomotion Is Mediated by the alpha-v-beta-5 Integrin Receptor, The Journal of Biological Chemistry, vol. 269, No. 43, pp. 26928-26932, Oct. 1994.
Nip et al., The role of the Integrin vitronectin receptor, alpha-v-beta-3 in melanoma metastasis, Cancer and Metastasis Reviews, 14, pp. 241-252, 1995.
Raynal et al., Bone Sialoprotein Stimulates in vitro Bone Resorption, Endocrinology, vol. 137, No. 6, pp. 2347-2354, 1996.
Schvartz et al., Vitronectin, The International Journal of Biochemistry & Cell Biology, 31, pp. 539-544, 1999.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Blaszykowski, Christophe et al.; “N-Silyl-Tethered Radical Cyclizations: A New Synthesis of γ-Amino Alcohols”; 2003,Organic Letters, vol. 5, No. 8, pp. 1341-1344.
Duggan, Mark E. et al.; “Nonpeptide αvβ3Antagonists. 1. Transformation of a Potent, Integrin-Selective αllbβ3Antagonist into a Potent αvβ3Antagonist”; 2000,J. Med. Chem., vol. 43, pp. 3736-3745.
Ensch, Corinne et al.; “Enantioselective Entry to theHomaliumAlkaloid Hoprominol; Synthesis of an (R,R,R)-Hoprominol Derivative”; 2003,Helvetica Chimica Acta.vol. 86, pp. 233-246.
Gray, C.J. et al.; “The Synthesis of An α-Azaornithine Derivative and its Reaction with Trypsin”; 1975,Tetrahedran, vol. 31, pp. 2940-2943.
Hood, John D. et al.; “Tumor Regression by Targeted Gene Delivery to the Neovasculature”; 2002, Science, vol. 296, pp. 2404-2407.
Mattingly, Phillip G.; “Mono-Protected Diamines. N2-tert-Butoxycarbonyl α,co-Alkanediamine Hydrochiorides from Amino alcohols”; 1990,Synthesis Papers, pp. 366-368.
Burnett, Christopher A. et al.; “Synthesis, in vitro, and in vivo characterization of an integrin αvβ3-targeted molecular probe for optical imaging of tumor”; 2005,Bioorganic&Medicinal Chemistry, vol. 13, pp. 3763-3771.
Burnett Christopher A.
Danthi S. Narasimhan
Li King C.
Heines M. Henry
Rao Deepak
The United States of America as represented by the Secretary of
Townsend and Townsend / and Crew LLP
LandOfFree
Integrin α-v β-3 antagonists for use in imaging... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin α-v β-3 antagonists for use in imaging..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin α-v β-3 antagonists for use in imaging... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3822834